Open Access

Integrating EPA based therapy in the management of residual risk.

Topic: Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)
Sponsored by PACE-CME

Congress Session

About the speaker

Professor Philippe Gabriel Steg

Hospital Bichat-Claude Bernard, Paris (France)
47 presentations
2 followers

2 more presentations in this session

Unravelling the triglycerides story: Lessons from genetics and clinical trials.

Speaker: Professor P. Libby (Boston, US)

Thumbnail

EPA based therapy in CAD: What do we know?

Speaker: Professor L. Tokgozoglu (Ankara, TR)

Thumbnail

Access the full session

Tackling residual risk beyond LDL-c therapy: The emerging role of EPA & triglycerides

Speakers: Professor P. Steg, Professor P. Libby, Professor L. Tokgozoglu
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Related content

ESC Premium Access

Endothelial barrier function and post-COVID consequences

27 August 2021

ESC Premium Access

Heart failure as a complication of covid-19 infection: systematic review and meta-analysis

27 August 2021

ESC Premium Access

Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage

27 August 2021

This platform is supported by

logo Novo Nordisk